TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22200383

Group type: EXPERIMENTAL
Intervention: Active US therapy (20% duty cycle, 1MHz, average temporal intensity: 0.2W/cm(2), therapeutic dose: 112.5J/cm(2))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham US therapy (no sound-head crystal)
Number of subjects: 27
Study: 21047602

Group type: EXPERIMENTAL
Intervention: 3 × 1 ml Orthovisc(®) hyaluronic acid injections
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1 ml single dose Orthovisc(®) hyaluronic acid injections
Number of subjects: 26

Group type: COMPARATOR
Intervention: 2 ml single dose Orthovisc(®) hyaluronic acid injections
Number of subjects: 26

Group type: COMPARATOR
Intervention: 3 ml single dose Orthovisc(®) hyaluronic acid injections
Number of subjects: 26
Study: 17685257

Group type: EXPERIMENTAL
Intervention: Chemotherapy with irinotecan + 5-FU + leucovorin
Number of subjects: 204

Group type: COMPARATOR
Intervention: Supportive care alone (control group)
Number of subjects: 204
Study: 14970837

Group type: EXPERIMENTAL
Intervention: Mixed-nutrient (MN) beverage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sugar-only (SO) beverage
Number of subjects: 20
Study: 11856774

Group type: EXPERIMENTAL
Intervention: SYNSORB Pk treatment (n = 19)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment (n = 12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dialysis required (acute phase)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acute phase vs. convalescence
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall bFGF levels
Number of subjects: 31
Study: 9420337

Group type: EXPERIMENTAL
Intervention: Radioiodine
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Radioiodine followed by prednisone
Number of subjects: 443

Group type: COMPARATOR
Intervention: Methimazole
Number of subjects: 443
Study: 7702016

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of pure fat or carbohydrate (2092 kJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intragastric infusions of fat or carbohydrate (2092 kJ)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow intragastric infusions of fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow intragastric infusions of carbohydrate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orally derived energy (2092-kJ yogurt preloads)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 12
Study: 2614659

Group type: EXPERIMENTAL
Intervention: ATT-INT (counseling designed to alter attributions for unwanted pregnancy)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: EXP-INT (counseling designed to raise coping expectations)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control (standard counseling)
Number of subjects: 283
Study: 605738

Group type: EXPERIMENTAL
Intervention: Suprapubic drainage via Intracath device
Number of subjects: 55

Group type: COMPARATOR
Intervention: Urethral drainage via Foley Catheter
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Suprapubic drainage
Number of subjects: 55

Group type: COMPARATOR
Intervention: Urethral drainage
Number of subjects: 55
Study: 30079951

Group type: EXPERIMENTAL
Intervention: Iron supplementation (200 mg of ferrous fumarate weekly for 3 months)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Iron supplementation with nutrition education
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 131
Study: 26151734

Group type: EXPERIMENTAL
Intervention: Sesamin 200 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 25805668

Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) for smoking abstinence
Number of subjects: 184

Group type: COMPARATOR
Intervention: Noncontingent vouchers (NCV)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) combined with motivational interviewing (MI)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) combined with brief advice (BA)
Number of subjects: 184
Study: 23640622

Group type: EXPERIMENTAL
Intervention: Individualized dialysate sodium concentration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard dialysate sodium concentration (138 mmol/L)
Number of subjects: 40
Study: 20884297

Group type: EXPERIMENTAL
Intervention: HBVaxPro monovalent hepatitis B vaccine
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Engerix B monovalent hepatitis B vaccine
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Hexavac
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Infanrix hexa
Number of subjects: 1543
Study: 18209262

Group type: EXPERIMENTAL
Intervention: Counseling and educational map
Number of subjects: 237

Group type: COMPARATOR
Intervention: Counseling only (Control group #1)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard care (Control group #2)
Number of subjects: 237
Study: 15087038

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Reduced Glutathione (GSH)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 62
Study: 12032111

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study: 9810446

Group type: EXPERIMENTAL
Intervention: CP-0127 (3.0 micrograms/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CP-0127
Number of subjects: 20
Study: 7759671

Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electroencephalographic (EEG) biofeedback
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Deep pressure/touch therapies
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stress‐challenge treatments
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Confrontational scare treatments
Number of subjects: 5
Study: 2496000

Group type: EXPERIMENTAL
Intervention: Enprostil (35 mu b.i.d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cimetidine (400 mg b.i.d)
Number of subjects: 80
Study: 769560

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31432562

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vaginal progesterone
Number of subjects: 300
Study: 31173130

Group type: EXPERIMENTAL
Intervention: Deep learning model (HeadXNet) augmentation
Number of subjects: 818

Group type: COMPARATOR
Intervention: No augmentation
Number of subjects: 818
Study: 28815552

Group type: EXPERIMENTAL
Intervention: Connect-Home intervention
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual discharge planning (comparison dyads)
Number of subjects: 145
Study: 26666596

Group type: EXPERIMENTAL
Intervention: Diet and exercise treatment for 3-6 months to reduce body weight by >5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 23682110

Group type: EXPERIMENTAL
Intervention: Macitentan (10 mg once daily)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 178
Study: 21802649

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.4 g/kg (low dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g/kg (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (all doses)
Number of subjects: 0
Study: 19046833

Group type: EXPERIMENTAL
Intervention: Preventive intervention targeting disruptive behavior problems
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 477
Study: 16960474

Group type: EXPERIMENTAL
Intervention: Intrathecal triamcinolone acetonide (6 injections every third day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MIX)
Number of subjects: 0
Study: 15645893

Group type: EXPERIMENTAL
Intervention: 14% hydrogen-peroxide whitening strips
Number of subjects: 31

Group type: COMPARATOR
Intervention: 9.5% hydrogen-peroxide custom-tray-based system
Number of subjects: 31
Study: 11726088

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9161943

Group type: EXPERIMENTAL
Intervention: 5 mg oral vitamin K1 supplementation per week for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: No supplementation for 4 weeks
Number of subjects: 18
Study: 7910126

Group type: EXPERIMENTAL
Intervention: Khat (0.8 mg/kg body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Alkaloid-free khat (placebo)
Number of subjects: 6
Study: 3115546

Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study: 31813317

Group type: EXPERIMENTAL
Intervention: Videoconference administration of MoCA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Face-to-face administration of MoCA
Number of subjects: 48
Study: 31916418

Group type: EXPERIMENTAL
Intervention: Quizartinib after overnight fasting (n = 34)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Quizartinib after a high-fat, high-calorie meal (n = 30)
Number of subjects: 64
Study: 29871369

Group type: EXPERIMENTAL
Intervention: Upper one-third joint technique (group U)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Lower one-third joint technique (group L)
Number of subjects: 181
Study: 27271500

Group type: EXPERIMENTAL
Intervention: SpeechEasy® device used daily for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: 12-week fluency promotion protocol with techniques based on fluency shaping and stuttering modification
Number of subjects: 18
Study: 22487170

Group type: EXPERIMENTAL
Intervention: Daily physical education (5 × 45 min/week) and adapted motor training if needed
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (PE two lessons/week)
Number of subjects: 220
Study: 21778278

Group type: EXPERIMENTAL
Intervention: High-sodium diet (HS, aim 200 mmol Na(+)/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low-sodium diet (LS, aim 50 mmol Na(+)/day)
Number of subjects: 63
Study: 20007734

Group type: EXPERIMENTAL
Intervention: Nabilone (0.5-1.0 mg before bedtime)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Amitriptyline (10-20 mg before bedtime)
Number of subjects: 31
Study: 18445635

Group type: EXPERIMENTAL
Intervention: Cefoxitin and doxycycline
Number of subjects: 682
Study: 15506862

Group type: EXPERIMENTAL
Intervention: More specific feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback specificity
Number of subjects: 0
Study: 11920267

Group type: EXPERIMENTAL
Intervention: Oral fludarabine phosphate on a full stomach
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral fludarabine phosphate on a fasted stomach
Number of subjects: 18
Study: 9439551

Group type: EXPERIMENTAL
Intervention: Leucine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Arginine infusion
Number of subjects: 8
Study: 7947430

Group type: EXPERIMENTAL
Intervention: 2% lidocaine HCl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine HCl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine HCl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion
Number of subjects: 10
Study: 3661609

Group type: EXPERIMENTAL
Intervention: Sucralfate (Carafate) 1 g
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cimetidine (Tagamet) 300 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo 1 g
Number of subjects: 28
Study: 30408319

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PCT)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Immediate surgery (IS)
Number of subjects: 426
Study: 29453671

Group type: EXPERIMENTAL
Intervention: Glaritus® (0.4 IU/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lantus® (0.4 IU/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Glaritus®
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lantus®
Number of subjects: 40
Study: 27672353

Group type: EXPERIMENTAL
Intervention: Higher anxiety sensitivity (AS)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Regression analysis and longitudinal analysis with multilevel modeling (MLM)
Number of subjects: 136
Study: 25113283

Group type: EXPERIMENTAL
Intervention: Zippy's Friends programme
Number of subjects: 766
Study: 23037714

Group type: EXPERIMENTAL
Intervention: Toronto criteria
Number of subjects: 2329

Group type: EXPERIMENTAL
Intervention: PRIAS criteria
Number of subjects: 2329

Group type: EXPERIMENTAL
Intervention: Cambridge data
Number of subjects: 2329

Group type: EXPERIMENTAL
Intervention: Nomogram based on Toronto criteria
Number of subjects: 2329
Study: 20053878

Group type: EXPERIMENTAL
Intervention: Higher-DHA group (1% DHA)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (0.3% DHA)
Number of subjects: 127
Study: 17628562

Group type: EXPERIMENTAL
Intervention: Diclofenac plus paracervical block
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Meperidine plus diclofenac
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Meperidine alone
Number of subjects: 113
Study: 16390757

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 383
Study: 11466599

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (n=46)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Psychodynamic treatment (n=52)
Number of subjects: 98
Study: 9236433

Group type: EXPERIMENTAL
Intervention: Intravenous and oral carvedilol treatment
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 8433880

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 376
Study: 2441593

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 32
Study: 30318090

Group type: EXPERIMENTAL
Intervention: Co-careldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31693806

Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin‐clavulanate (1 g and 200 mg, respectively) administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo administered three times a day for 2 days, starting less than 6 hours after cardiac arrest.
Number of subjects: 194
Study: 28577545

Group type: EXPERIMENTAL
Intervention: Intervention (two dietary consultations and access to twice‐weekly exercise groups)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control (routine prenatal care)
Number of subjects: 606
Study: 25082656

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no allopurinol treatment)
Number of subjects: 30
Study: 22972448

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 0
Study: 21807696

Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg daily from 18 to 22 weeks' gestation through parturition)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 849
Study: 18593746

Group type: EXPERIMENTAL
Intervention: Antimicrobial impregnated CVCs
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard triple-lumen CVCs
Number of subjects: 118
Study: 17014635

Group type: EXPERIMENTAL
Intervention: Face washing twice a day with a standard mild cleanser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face washing once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face washing four times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face washing twice a day (control group)
Number of subjects: 0
Study: 15310641

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 10664923

Group type: EXPERIMENTAL
Intervention: IS‐5‐MN 20 mg immediate release
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: IS‐5‐MN 50 mg sustained release
Number of subjects: 15
Study: 9297869

Group type: EXPERIMENTAL
Intervention: i.v. omeprazole, 40 mg bolus followed by 80 mg/day by continuous infusion for 3 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: i.v. ranitidine 50 mg i.v. bolus followed by 400 mg/day i.v., continuous infusion for 3 days
Number of subjects: 45
Study: 8345983

Group type: EXPERIMENTAL
Intervention: IVGG (400 mg/kg/day for 4 consecutive days)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 291
Study: 31505367

Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback intervention (Active intervention group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control intervention (Control intervention group)
Number of subjects: 28
Study: 30152049

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) of DEC and albendazole
Number of subjects: 627
Study: 26801098

Group type: EXPERIMENTAL
Intervention: Exercise training (150 min weekly of combined aerobic and resistance training)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard follow-up (Control)
Number of subjects: 137
Study: 24999518

Group type: EXPERIMENTAL
Intervention: Mom's Empowerment Program (10-session evidence-based intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 120
Study: 22304620

Group type: EXPERIMENTAL
Intervention: Mentholated cream plus oxygenated glycerol triesters (MC + OGTs)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mentholated cream (MC)
Number of subjects: 66
Study: 20919804

Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Poliglecaprone-25 suture
Number of subjects: 117

Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 117
Study: 18514323

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients with shorter duration of antipsychotic drug exposure
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 29
Study: 16433076

Group type: EXPERIMENTAL
Intervention: Video information package
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 12578787

Group type: EXPERIMENTAL
Intervention: Fluorescein angiography classification by retinal specialists
Number of subjects: 40
Study: 10473837

Group type: EXPERIMENTAL
Intervention: Exposure to hand‐transmitted vibration
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (31 subjects)
Number of subjects: 107
Study: 8740043

Group type: EXPERIMENTAL
Intervention: 15 mg phenelzine every other day, then 15 mg daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 0
Study: 1846872

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) + 5 mg medroxyprogesterone acetate (days 15-25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1.25 mg CEE + placebo (days 15-25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE (days 1-25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1.25 mg CEE (days 1-25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (days 15-25)
Number of subjects: 48
Study: 6760968

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg oral dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31232940

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg twice daily 1 day before and 3 days after the operation)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control (hydration from 12 hours before to 12 hours after contrast administration)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Hydration
Number of subjects: 220
Study: 29209721

Group type: EXPERIMENTAL
Intervention: High-cutoff hemodialysis (46 patients)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional hemodialysis (48 patients)
Number of subjects: 98
Study: 28031304

Group type: EXPERIMENTAL
Intervention: Web-based quality assurance (QA) tool for ultrasound exams
Number of subjects: 0
Study: 25916131

Group type: EXPERIMENTAL
Intervention: Intravenous laser therapy (10-day course) using 'matrix-vlok' apparatus, wavelength 0.405 microns, radiation power 1-1.5 mW, continuous mode
Number of subjects: 112
Study: 22963759

Group type: EXPERIMENTAL
Intervention: Guillotine technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cold steel dissection
Number of subjects: 100
Study: 19229822

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17497518

Group type: EXPERIMENTAL
Intervention: PARC curriculum
Number of subjects: 9571

Group type: COMPARATOR
Intervention: Traditional curriculum
Number of subjects: 9571
Study: 15149168

Group type: EXPERIMENTAL
Intervention: Melan-A peptide with immune adjuvant AS02B (QS21 and MPL)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Melan-A peptide in IFA
Number of subjects: 49
Study: 11471442

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution (NVH) with blood withdrawal of 6-8 ml.kg-1 and intravenous colloid substitution
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard transfusion protocol (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Normovolemic hemodilution (NVH)
Number of subjects: 38
Study: 10024217

Group type: EXPERIMENTAL
Intervention: Milk with Lactobacillus GG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk (without Lactobacillus GG)
Number of subjects: 0